Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324587 | 0.76 | LMNA (0.58) | SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL8240316 | 0.70 | RAB9A (0.71) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL13841479 | 0.70 | RAB9A (0.68) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL10665125 | 0.69 | RAB9A (0.66) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL9885823 | 0.69 | ALDH1A1 (0.67) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL30440441 | 0.69 | RAB9A (0.66) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL2190227 | 0.69 | RAB9A (0.66) | SMN1; SMN2RAB9ANPC1ALDH1A1TSHR | |
| SCHEMBL1770271 | 0.69 | HSD11B1 (0.52) | NPC1ALDH1A1TSHRKMT2A | |
| SCHEMBL3387787 | 0.68 | RAB9A (0.64) | SMN1; SMN2RAB9ANPC1KMT2AMAPT | |
| SCHEMBL3387780 | 0.68 | RAB9A (0.64) | SMN1; SMN2RAB9ANPC1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | SMN1; SMN2 4801/4885RAB9A 2432/4885NPC1 1106/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | SMN1; SMN2 4612/4885RAB9A 2176/4885NPC1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.